Pharmaceutical Technology

OCTOBER 17, 2024

Strategic restructuring will support the ongoing launch of the oral postpartum depression drug, Zurzuvae, and extend Sage’s cash runway.

Drugs 147

Drugs 147

Bio Pharma Dive

OCTOBER 17, 2024

Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.

Drugs 340

Drugs 340

XTalks

OCTOBER 17, 2024

The US Food and Drug Administration (FDA) has granted clearance to imaging and healthcare IT company Heidelberg Engineering’s Flex Module, a multimodal, diagnostic imaging-only platform designed for imaging the posterior segment of pediatric and adult patients in a supine (face up) position. Being able to image macular and optic nerve pathologies in the supine position ensures that vulnerable individuals can receive timely and sight-saving diagnoses and treatments.

Engineer 104

Engineer FDA Approval Marketing Drugs 104

Bio Pharma Dive

OCTOBER 17, 2024

The restructuring, which follows clinical setbacks in Alzheimer’s, Parkinson’s and tremor, will also involve the departure of five senior executives.

Drugs 286

Drugs 286

Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

Pharmaceutical Technology

OCTOBER 17, 2024

The company’s keratoconus medication, Epioxa, was effective in a Phase III trial, with plans to file for submission with the US Food and Drug Administration (FDA).

FDA Approval 246

FDA Approval Trials Drugs 246

Bio Pharma Dive

OCTOBER 17, 2024

The French drugmaker will invest 300 million euros into a new entity that will develop lead isotope-based therapies for cancer under the Orano Med brand.

Branding 285

Branding Development 285

Pharmaceutical Technology

OCTOBER 17, 2024

Acadia Pharmaceuticals has received marketing authorisation from Health Canada for DAYBUE (trofinetide) to treat Rett syndrome.

Marketing 182

Marketing 182

Bio Pharma Dive

OCTOBER 17, 2024

The deal offers Lexicon a cash infusion of $25 million as the company tries to broaden use of the heart failure and diabetes medication.

Drugs 170

Drugs 170

Pharma Times

OCTOBER 17, 2024

The London hub is home to life sciences companies including Novartis, Engitix and invoX Pharma

Life Science 136

Life Science 136

Pharmaceutical Technology

OCTOBER 17, 2024

Bavarian Nordic’s MVA-BN vaccine showed equivalent antibody response and safety between teenagers and adults in an NIH study.

Vaccine 130

Vaccine Vaccination Antibody 130

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

Pharma Times

OCTOBER 17, 2024

The two-year programme will use virtual reality technology to teach essential skills

Manufacturing 136

Manufacturing Medicine Life Science 136

Pharmaceutical Technology

OCTOBER 17, 2024

Fresenius Kabi and Cellular Origins have announced a partnership to advance cell and gene therapy (CGT) by automating manufacturing.

Manufacturing 130

Manufacturing Gene Therapy Gene 130

Fierce Pharma

OCTOBER 17, 2024

AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system innovation in the space as drugmakers sought to avoid the common pitfall | The 24-hour Parkinson's disease therapy crossed the FDA finish line after an initial manufacturing-related rejection last year and another snub in June.

Manufacturing 125

Manufacturing 125

Pharmaceutical Technology

OCTOBER 17, 2024

Lexicon Pharmaceuticals has entered a licensing agreement with Viatris to commercialise sotagliflozin outside the US and Europe.

Licensing 130

Licensing Licensing 130

Advertisement

Clinical Supply

pharmaphorum

OCTOBER 17, 2024

The first human skin atlas is helping researchers to understand how skin forms, the mechanisms behind disorders, and could usher in scarless healing

Research 115

Research 115

Drug Patent Watch

OCTOBER 17, 2024

Regulatory Considerations for Biosimilar Analytical Similarity Assessments Biosimilars, or follow-on biologics, are biopharmaceuticals that are highly similar to an already approved biological product.

Production 115

Production 115

pharmaphorum

OCTOBER 17, 2024

Sage has launched another round of layoffs as it deals with the fallout of dropping a key pipeline drug for Alzheimer's and Parkinson's

Drugs 114

Drugs 114

XTalks

OCTOBER 17, 2024

The US Food and Drug Administration (FDA) has granted approval for Novocure’s Optune Lua device to be used in combination with existing treatments for metastatic non-small cell lung cancer (NSCLC). Designed for adults who have progressed after platinum-based chemotherapy, Optune Lua can be used alongside immune checkpoint inhibitors, such as programmed death receptor-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockers, or the chemotherapy drug docetaxel.

Clinical Trials 111

Clinical Trials Clinical Trials Trials FDA Approval 111

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

pharmaphorum

OCTOBER 17, 2024

NICE backs NHS use of Roche's Alecensa as first adjuvant therapy for ALK+ NSCLC, and peri-operative use of MSD's Keytruda for all-comer NSCLC patients

105

105

BioPharma Reporter

OCTOBER 17, 2024

Investors and big pharma companies are waking up to the potential of techbio companies after years of avoidance, say experts at TechBio UK 2024, an event run by the BioIndustry Association (BIA).

Pharma Companies 104

Pharma Companies 104

Outsourcing Pharma

OCTOBER 17, 2024

The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeckâs neuroscience pipeline.

Drugs 99

Drugs 99

Drug Channels

OCTOBER 17, 2024

Today’s guest post comes from Greg Skalicky, President, EVERSANA and Faruk Abdullah, President, Professional Services & Chief Business Officer, EVERSANA Greg and Faruk walk through the marketplace pressures driving Direct-to-Patient commercialization models. They argue that a technology-enabled infrastructure, combined with clinical and reimbursement support specialists, can improve patients' access to new therapies, shorten the time to therapy, and enable better overall clinical outco

Drugs 96

Drugs 96

Advertisement

Clinical Supply

pharmaphorum

OCTOBER 17, 2024

Join us on Day One of Frontiers Health 2024 as we welcome speakers such as Dave deBronkart, Jacob Uszkoreit, Bart de Witte, and more to discuss the latest innovations in healthcare and digital health.

94

94

Fierce Pharma

OCTOBER 17, 2024

With the clade 1 outbreak of mpox (formerly monkeypox) raging through the Congo and other countries in Central Africa, younger people have become markedly

Immune Response 80

Immune Response 80

Pharma Marketing Network

OCTOBER 17, 2024

As we approach 2025, the pharmaceutical industry is witnessing a seismic shift in marketing strategies, driven by technological advancements and evolving consumer expectations. These trends are not only transforming how pharmaceutical companies engage with healthcare professionals and patients but also shaping the future of healthcare delivery. This article explores the top pharma marketing trends that are set to redefine the landscape in the coming years.

Marketing 52

Marketing Pharma Companies Regulation Production 52

Fierce Pharma

OCTOBER 17, 2024

Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has abandoned a liver disease collaboration with Yuhan. | Eli Lilly is making a series of investments in China. Gilead Sciences has abandoned a liver disease collaboration with Yuhan. A study suggests Leqembi's vial design could cost Medicare hundreds of millions of dollars in waste each year.

Manufacturing 67

Manufacturing 67

Advertisement

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

Clinical Trials

Pharma Marketing Network

OCTOBER 17, 2024

In an increasingly competitive pharmaceutical landscape, the significance of healthcare branding has never been more pronounced. As we approach 2025, the ability of pharmaceutical companies to effectively craft and communicate their brand identity will play a pivotal role in determining their market success. This article delves into the essence of healthcare branding and explores strategic approaches for pharma marketing, emphasizing the importance of digital platforms and the measurement of bra

Branding 52

Branding Marketing Research 52

Fierce Pharma

OCTOBER 17, 2024

After Viatris’ CEO earlier this year promised to be “opportunistic” about future business development moves, the company is making good on that pledge with a new licensing pact to bolster its cardi | Viatris is ponying up $25 million upfront to obtain the rights to sell Lexicon Pharmaceuticals’ SGLT1/SGLT2 heart med sotagliflozin, known commercially as Inpefa, in all global markets beyond the U.S. and Europe.

Licensing 67

Licensing Licensing Business Development Marketing 67

Pharmaceutical Commerce

OCTOBER 17, 2024

Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the key takeaways of this year's keynote speech.

52

52

XTalks

OCTOBER 17, 2024

World Osteoporosis Day (WOD), observed annually on October 20, is a global event dedicated to raising awareness about the prevention, diagnosis and treatment of osteoporosis and other metabolic bone diseases. For 2024, worldosteoporosisday.org has launched a new campaign called “Say No to Fragile Bones.” It highlights the importance of early action in preserving bone health.

Life Science 52

Life Science 52

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research